Instead of the combination treatment with cytotoxic chemotherapy and radiation therapy, molecular targeted drugs is testing in many clinical trials. Because unexpected adverse events were reported in the previous trials using molecular targeted drugs with radiotherapy, attention should be paid to this combination. In EGFR mutated lung cancer, gefitinib with radiotherapy is testing.